Evaluation
U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs
U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence
EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION
Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation
AstraZeneca Appoints Iskra Reic as New International Operations Lead Following Investigation into China Executive
AstraZeneca, Iskra Reic, Leon Wang, China investigation, international operations lead
Senators Wyden and Brown Call for FTC Investigation into PBM “Co-Manufacturing” Practices
PBM reforms, FTC investigation, co-manufacturing, pharmacy benefit managers, drug costs, competition, healthcare industry
Senators Wyden and Brown Urge FTC to Expand Investigation into PBMs’ Anti-Competitive Practices
Pharmacy Benefit Managers (PBMs), Anti-Competitive Practices, FTC Investigation, Co-Manufacturing Agreements, Drug Prices, Healthcare Reform
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
US FTC Intensifies Patent Crusade with Investigation into Teva’s Inhaler IP
US Federal Trade Commission, Teva Pharmaceuticals, Patent Investigation, Inhaler IP, Anticompetitive Practices, Generic Competition
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation
Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency